Multiple sclerosis: treatment Tuesday, May 31, 2011, 11:30 – 12:30 Safety and efficacy of rituximab in neuromyelitis optica spectrum disorder M. Radaelli, L. Moiola, D
The NSCIA Difference Founded in 1948, the National Spinal Cord Injury Association is the nation’s oldest and largest civilian organization dedicated to improving the quality of life for hundreds of thousands of Americans living with the results of spinal cord injury and disease (SCI/D) and their families. This number grows by thirty newly-injured people each day. At NSCIA, we educate and empower survivors of spinal cord injury and disease to achieve and maintain the highest levels of independence, health and personal fulfillment
Recurrent attacks of optic neuritis and myelitis are the hallmarks of both neuromyelitis optica (NMO) and multiple sclerosis (MS). NMO immunoglobulin G (NMO-IgG), which recognizes astrocytic aquaporin-4 (AQP4) water channels, is a specific serum autoantibody that distinguishes NMO from MS. The pathogenic role of the anti-AQP4 antibody (AQP4-Ab, NMO-IgG) in NMO has been speculated based on several studies in vitro.
We report a 25-year-old woman who developed optic neuritis and encephalomyelitis following primary Sjogren’s syndrome (SjS).
Lidocaine unmasks silent symptoms and eases neuropathic pain in multiple sclerosis patients; however, the effects of lidocaine in neuromyelitis optica have never been reported. We describe the case of a 59-year-old Japanese woman with neuromyelitis optica spectrum disorder who developed optic neuritis 1 day after intravenous lidocaine injection for treating allodynia. Her symptom seemed to result from a relapse of neuromyelitis optica induced by lidocaine administration, and not because of the transient effects of intravenous lidocaine administration.
Objetive: To demonstrate the occurrence of intractable hiccup and nausea (IHN) as first symptoms in Neuromyelitis optica (NMO) patients who developed cervical myelitis. Background: IHN are unique symptoms of NMO, which is a neurological disorder mainly characterized by optic neuritis and myelitis. Methods: We reviewed the medical records of 25 cases of relapsing NMO seen at the Ramos Mejia Hospital in Argentina during the period from 2006 to 2010.
Background: Although it has been well established that vaccination does not increase the risk of relapse in patients with multiple sclerosis (MS), no study on the influence of immunization on neuromyelitis optica spectrum disorder (NMOsd) has been conducted. As NMO differs from MS in a number of aspects, including its immunopathogenetic mechanisms, vaccination may have some influence on the occurrence of new relapses